In Austria, sales of Genito Urinary System and Sex Hormones per capita have shown a decreasing trend from 2024 to 2028. Starting at 4.6 in 2024, the sales are forecasted to decline to 3.9 by 2028. This decrease represents a significant decline in annual sales per capita.
Year-on-year variations:
- 2024 to 2025: -4.35%
- 2025 to 2026: -4.55%
- 2026 to 2027: -2.38%
- 2027 to 2028: -4.88%
Over the most recent years from 2023 to 2024, there was no variation as the values for these two years were not provided. CAGR (Compound Annual Growth Rate) over the five-year period indicates an average annual decline of similar magnitude.
Future trends to watch for include potential innovations in pharmaceutical treatments, the impact of demographic aging, and changes in healthcare policies which could influence demand dynamics for Genito Urinary System and Sex Hormones medications in Austria.
